Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Updated poster following beta v3 release. In preparation for Pharmacology Futures, Edinburgh Immunology Symposium and Word Congress of Pharmacology (Kyoto)

Published in: Science
  • Be the first to comment

  • Be the first to like this


  1. 1. GtoImmuPdb Portal Aims ● A unique access-point to immunological data in GtoPdb ● An expert-curated database containing immunological information ● Develop new pages and extend search mechanism for immunological data ● Assist in the identification of novel therapeutic targets ● Assist in identifying small-molecules for experimental investigation S. D. Harding1 , E. Faccenda1 , S. Ireland1 , A. J. Pawson1 , J. L. Sharman1 , C. Southan1 , S. P. Alexander2 , S. Anderton3 , C. Bryant4 , A. P. Davenport5 , C. Doerig6 , D. Fabbro7 , F. Levi-Schafer8 , M. Spedding9 , J. A. Davies1 1Centre for Integratie Physiology, School of Biomedical Sciences, Uniiersity of Edinburgh, Edinburgh, UNITED KINGDOM, 2Life Sciences, Uniiersity of Notngham, Notngham, UNITED KINGDOM,3MRC Centre for Infammaton Research, QMRI, Uniiersity of Edinburgh, Edinburgh, UNITED KINGDOM, 4 Veterinary Medicine, Uniiersity of Cambridge, Cambridge, UNITED KINGDOM,5 Clinical Pharmacology Unit, Uniiersity of Cambridge, Cambridge, UNITED KINGDOM, 6 Department of Microbiology, Monash Uniiersity, Clayton, AUSTRALIA, 7PIQUR Therapeutcs AG, Basel, SWITZERLAND, 8School of Pharmacy, Insttute for Drug Research, Hebrew Uniiersity of Jerusalem, Jerusalem, ISRAEL, 9Spedding Research Solutons SARL, Le Vesinet, FRANCE. Introduction Background Immune/inflammatory/infection responses and disorders are a major focus of pharmacological R&D. Chronic diseases, aspects of ageing and progress of infection all have, or depend strongly on, an immune, or inflammatory, component. Being able to modulate these more effectively with better drugs would be immensely valuable. Development of these drugs will benefit from improved data exchange between the immunology expert and pharmacology expert communities. What is the Guide to IMMUNOPHARMACOLOGY Our Wellcome Trust-funded project to produce the IUPHAR Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb) addresses this need by providing a new portal to the existing IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb), that is both 'immunologist-friendly' for pharmacological information and 'pharmacologist-friendly' for accessing immunological agents and targets. GtoImmuPdb will be a freely-available, regularly updated and richly annotated resource. Curated by expert NC-IUPHAR* sub-committees, including additional contributors with expertise in immunity, inflammation and kinase biology. GtoImmuPdb Data The GtoP database has been enriched by tagging targets & ligands of immunological relevance and by linking these to immunological processes, cell types and relevant diseases. Beta-version 3.0 available at: The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) is an open access resource providing overviews of key properties, background reading and selective ligands of a wide range of biological targets. The searchable database provides quantitative information on drug targets and the prescription medicines and experimental drugs that act on them. For ligands, data on approved status, clinical use and mechanism of action are included. References * International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification 1. Harding SD, et al. (2018) The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and expansion to encompass the new Guide to IMMUNOPHARMACOLOGY. Nucl. Acids Res. 46(D1):D1091-D1106 PMID: 29149325 Online version of this poster: Human targets in GtoPdb, 2018.2 release Ligand classes in GtoPdb, 2018.2 release The 2018.2 release (May 2018) of the database contains over 15,800 curated interactions across 2,872 human targets and 9,251 ligands. More specifically, the database contains 1,467 human targets that have quantitative interactions to a ligand. Immunological Data GtoImmuPdb presents a set of top-level immunological process and cell type categories against which targets in the database can be annotated and which form the basis of organising, navigating and searching for immunological process and cell type associations. As of 9 May 2017 GtoImmuPdb held 525 protein targets and 993 ligands tagged as being of immunological relevance. GtoImmuPdb uses ontologies (Cell, Gene & Disease) as controlled vocabularies against which to annotate. Immuno Cell Types B cells Dendritic cells Granulocytes Innate lymphoid cells Macrophages & monocytes Mast cells Natural killer cells Other T cells T cells Stromal cells Immuno Processes Antigen presentation Barrier integrity B cell (activation) Cellular signalling Chemotaxis & migration Cytokine production & signalling Immune regulation Immune system development Inflammation T cell (activation) Tissue repair Targets Ligands Cell types Processes Disease Target family pages use a toggle to switch between GtoPdb & GtoImmuPdb views Ligand lists highlight immuno relevant ligands with new icons. Here showing inhibitors of BTK IUPHAR Guide to IMMUNOPHARMACOLOGY 0 Displaying GtoImmuPdb data in detailed view of BTK Disease summary pages highlight target and ligands relevant to immunological disease. Here, showing ligands linked to Psoriasis – includes drug approval status and curatorial & clinical use comments Detailed view pages display associations between targets and immunological data These include detailed curator comments and links to external references Slideshare: http://// Twitter: @GuidetoPHARM